GLP-1-based therapies have no microvascular effects in type 2 diabetes mellitus

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 10, 2016, Pages 2125-2132

  Smits, Mark M ^a   Tonneijck, Lennart ^a   Muskiet, Marcel H A ^a   Hoekstra, Trynke ^a,b   Kramer, Mark H H ^a   Diamant, Michaela ^a   Serné, Erik H ^a   Van Raalte, Daniël H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

blood pressure; diabetes mellitus; DPP 4 inhibitors; GLP 1 receptor agonists; microcirculation

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; LIRAGLUTIDE; PLACEBO; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INCRETIN; PEPTIDE; VENOM;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CAPILLARY; TEST MEAL; TREATMENT DURATION; TREATMENT INDICATION; VIDEO MICROSCOPY; AGED; AGONISTS; ANGIOSCOPY; BLOOD; BLOOD FLOW; BLOOD FLOW VELOCITY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; LASER DOPPLER FLOWMETRY; MALE; METABOLISM; MICROCIRCULATION; MICROVASCULATURE; NETHERLANDS; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN; TIME FACTOR; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; AGED; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCRETINS; LASER-DOPPLER FLOWMETRY; LIRAGLUTIDE; MALE; MICROCIRCULATION; MICROSCOPIC ANGIOSCOPY; MICROSCOPY, VIDEO; MICROVESSELS; MIDDLE AGED; NETHERLANDS; PEPTIDES; REGIONAL BLOOD FLOW; SIGNAL TRANSDUCTION; SITAGLIPTIN PHOSPHATE; SKIN; TIME FACTORS; TREATMENT OUTCOME; VENOMS;

EID: 84983732337     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307930     Document Type: Article

References (41)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439. doi: 10.1152/physrev.00034.2006.
2. Gallwitz B. Extra-pancreatic effects of incretin-based therapies. Endocrine. 2014;47:360-371. doi: 10.1007/s12020-014-0223-0.
3. Gutterman DD, Chabowski DS, Kadlec AO, Durand MJ, Freed JK, Ait-Aissa K, Beyer AM. The human microcirculation: regulation of flow and beyond. Circ Res. 2016;118:157-172. doi: 10.1161/CIRCRESAHA.115.305364.
4. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788-1803. doi: 10.1161/CIRCRESAHA.114.301958.
5. Chai W, Zhang X, Barrett EJ, Liu Z. Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin?s metabolic action in the presence of insulin resistance. Diabetes. 2014;63:2788-2799. doi: 10.2337/db13-1597.
6. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007;293:E1289-E1295. doi: 10.1152/ajpendo.00373.2007.
7. Sjøberg KA, Holst JJ, Rattigan S, Richter EA, Kiens B. GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab. 2014;306:E355-E362. doi: 10.1152/ajpendo.00283.2013.
8. Subaran SC, Sauder MA, Chai W, Jahn LA, Fowler DE, Aylor KW, Basu A, Liu Z. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond). 2014;127:163-170. doi: 10.1042/CS20130708.
9. Dong Z, Chai W, Wang W, Zhao L, Fu Z, Cao W, Liu Z. Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab. 2013;304:E222-E228. doi: 10.1152/ajpendo.00473.2012.
10. Marques-Neto SR, Castiglione RC, Pontes A, Oliveira DF, Ferraz EB, Nascimento JH, Bouskela E. Effects of incretin-based therapies on neurocardiovascular dynamic changes induced by high fat diet in rats. PLoS One. 2016;11:e0148402. doi: 10.1371/journal.pone.0148402.
11. Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Pieters IC, Cahen DL, Diamant M, van Raalte DH. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open. 2015;5:e009579. doi: 10.1136/bmjopen-2015-009579.
12. van Genugten RE, Serné EH, Heymans MW, van Raalte DH, Diamant M. Postprandial microvascular function deteriorates in parallel with gradual worsening of insulin sensitivity and glucose tolerance in men with the metabolic syndrome or type 2 diabetes. Diabetologia. 2013;56:583-587. doi: 10.1007/s00125-012-2783-y.
13. Meijer RI, De Boer MP, Groen MR, Eringa EC, Rattigan S, Barrett EJ, Smulders YM, Serne EH. Insulin-induced microvascular recruitment in skin and muscle are related and both are associated with whole-body glucose uptake. Microcirculation. 2012;19:494-500. doi: 10.1111/j.1549-8719.2012.00174.x.
14. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003;285:E123-E129. doi: 10.1152/ajpendo.00021.2003.
15. Sjøberg KA, Rattigan S, Jeppesen JF, Lundsgaard AM, Holst JJ, Kiens B. Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short-And long-Term insulin resistance. J Physiol. 2015;593:2185-2198. doi: 10.1113/JP270129.
16. Smits MM, Muskiet MH, Tonneijck L, Kramer MH, Diamant M, van Raalte DH, Serné EH. GLP-1 receptor agonist exenatide increases capillary perfusion independent of nitric oxide in healthy overweight men. Arterioscler Thromb Vasc Biol. 2015;35:1538-1543. doi: 10.1161/ATVBAHA.115.305447.
17. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601-2610. doi: 10.1172/JCI118709.
18. de Jongh RT, Serné EH, IJzerman RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-Associated microangiopathy, hypertension, and insulin resistance. Circulation. 2004;109:2529-2535. doi: 10.1161/01.CIR.0000129772.26647.6F.
19. Dineen SL, McKenney ML, Bell LN, Fullenkamp AM, Schultz KA, Alloosh M, Chalasani N, Sturek M. Metabolic syndrome abolishes glucagon-like peptide 1 receptor agonist stimulation of SERCA in coronary smooth muscle. Diabetes. 2015;64:3321-3327. doi: 10.2337/db14-1790.
20. Baron AD, Clark MG. Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr. 1997;17:487-499. doi: 10.1146/annurev. nutr.17.1.487.
21. Coffman JD. Effects of endothelium-derived nitric oxide on skin and digital blood flow in humans. Am J Physiol. 1994;267(6 pt 2):H2087-H2090.
22. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43-52. doi: 10.1210/endo.130.1.1727716.
23. Serné EH, Gans RO, ter Maaten JC, Tangelder GJ, Donker AJ, Stehouwer CD. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension. 2001;38:238-242.
24. Serné EH, IJzerman RG, Gans RO, Nijveldt R, De Vries G, Evertz R, Donker AJ, Stehouwer CD. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes. 2002;51:1515-1522.
25. de Boer MP, Meijer RI, Newman J, Stehouwer CD, Eringa EC, Smulders YM, Serné EH. Insulin-induced changes in microvascular vasomotion and capillary recruitment are associated in humans. Microcirculation. 2014;21:380-387. doi: 10.1111/micc.12114.
26. Nilsson H, Aalkjaer C. Vasomotion: mechanisms and physiological importance. Mol Interv. 2003;3:79-89, 51. doi: 10.1124/mi.3.2.79.
27. Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serné EH, Smulders YM, Stehouwer CD. Meal-related increases in microvascular vasomotion are impaired in obese individuals: a potential mechanism in the pathogenesis of obesity-related insulin resistance. Diabetes Care. 2011;34(suppl 2):S342-S348. doi: 10.2337/dc11-s240.
28. Rattigan S, Clark MG, Barrett EJ. Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes. 1997;46:1381-1388.
29. Söderström T, Stefanovska A, Veber M, Svensson H. Involvement of sympathetic nerve activity in skin blood flow oscillations in humans. Am J Physiol Heart Circ Physiol. 2003;284:H1638-H1646. doi: 10.1152/ajpheart.00826.2000.
30. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, Low PA. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol. 2008;295:R874-R880. doi: 10.1152/ajpregu.00153.2008.
31. Nakatani Y, Kawabe A, Matsumura M, Aso Y, Yasu T, Banba N, Nakamoto T. Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using Holter electrocardiography and power spectrum analysis of heart rate variability. Diabetes Care. 2016;39:e22-e23. doi: 10.2337/dc15-1437.
32. Khoo EY, Wallis J, Tsintzas K, Macdonald IA, Mansell P. Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and catecholamines in healthy volunteers during exercise. Diabetologia. 2010;53:139-143. doi: 10.1007/s00125-009-1579-1.
33. Sato M, Dehvari N, Oberg AI, Dallner OS, Sandström AL, Olsen JM, Csikasz RI, Summers RJ, Hutchinson DS, Bengtsson T. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes. 2014;63:4115-4129. doi: 10.2337/db13-1860.
34. Newman JM, Dwyer RM, St-Pierre P, Richards SM, Clark MG, Rattigan S. Decreased microvascular vasomotion and myogenic response in rat skeletal muscle in association with acute insulin resistance. J Physiol. 2009;587(pt 11):2579-2588. doi: 10.1113/jphysiol.2009.169011.
35. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30:219-225.
36. Seals DR, Dinenno FA. Collateral damage: cardiovascular consequences of chronic sympathetic activation with human aging. Am J Physiol Heart Circ Physiol. 2004;287:H1895-H1905. doi: 10.1152/ajpheart.00486.2004.
37. Smits MM, van Raalte DH, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL. GLP-1 based therapies: clinical implications for gastroenterologists. Gut. 2016;65:702-711. doi: 10.1136/gutjnl-2015-310572.
38. Keske MA, Clerk LH, Price WJ, Jahn LA, Barrett EJ. Obesity blunts microvascular recruitment in human forearm muscle after a mixed meal. Diabetes Care. 2009;32:1672-1677. doi: 10.2337/dc09-0206.
39. Koska J, Sands M, Burciu C, D?Souza KM, Raravikar K, Liu J, Truran S, Franco DA, Schwartz EA, Schwenke DC, D?Alessio D, Migrino RQ, Reaven PD. Exenatide protects against glucose-And lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes. 2015;64:2624-2635. doi: 10.2337/db14-0976.
40. Torimoto K, Okada Y, Mori H, Otsuka T, Kawaguchi M, Matsuda M, Kuno F, Sugai K, Sonoda S, Hajime M, Tanaka K, Arao T, Tanaka Y. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:25. doi: 10.1186/s12933-015-0188-1.
41. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22. doi: 10.1056/NEJMoa1411892.